ImmunityBio's ANKTIVA plus BCG shows 71% complete response rate in bladder cancer study
IBRX•ImmunityBio announced published Phase 2/3 results showing a 71% complete response rate with ANKTIVA plus BCG in bladder cancer patients.
1. Study results
Published Phase 2/3 results in the Journal of Urology reported durable responses among patients with BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. Long-term findings showed sustained disease control, while most treatment-related adverse events were mild or moderate and no life-threatening or fatal treatment-related events were reported.
